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Abstract: Embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs) derived 
from somatic cells (SCs) provide promising resources for regenerative medicine and medical 
research, leading to a  daily identification of new cell lines. However, an efficient system to 
discriminate the cell lines is lacking. Here, we developed a quantitative system to discriminate 
the  three  cell  types,  iPSCs,  ESCs  and  SCs.  The  system  contains  DNA-methylation 
biomarkers  and  mathematical  models,  including  an  artificial  neural  network  and  support 
vector machines. All biomarkers were unbiasedly selected by calculating an eigengene score 
derived from analysis of genome-wide DNA methylations. With 30 biomarkers, or even with as 
few as 3 top biomarkers, this system can discriminate SCs from ESCs and iPSCs with almost 
100% accuracy, and with approximately 100 biomarkers, the system can distinguish ESCs 
from iPSCs with an accuracy of 95%. This robust system performs precisely with raw data 
without  normalization as well  as with converted data in which the continuous methylation 
levels  are  accounted.  Strikingly,  this  system  can  even  accurately  predict  new  samples 
generated  from  different  microarray  platforms  and  the  next-generation  sequencing.  The 
subtypes of cells,  such as female and male iPSCs and fetal  and adult SCs, can also be 
discriminated with this system. Thus, this quantitative system works as a novel general and 
accurate framework for discriminating the three cell types, iPSCs, ESCs, and SCs and this 
strategy  supports  the  notion  that  DNA-methylation  generally  varies  among the  three  cell 
types. 
Introduction
Embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs) provide important 
resources for regenerative medicine and medical research [1,2,3,4,5]. Given the potential of 
these stem cell lines, the numbers of identified cell lines accumulate daily. In order to tap into 
this great resource, an accurate system to discriminate the cell lines is required. However, 
such a discriminant system remains to be developed. 
Traditionally,  biomarkers  derived  from  well-characterized  individual  molecules  have  been 
used to distinguish somatic cells (SCs) versus pluripotent cells (PCs), including iPSCs and 
ESCs  [6,7].  PCR  and  immunostaining  can  be  used  to  further  aid  the  biomarkers  in 
distinguishing SCs from PCs [6]. However, applying the biomarkers to inherent multipotent 
cell lines could mislead the results due to the instabilities of multipotent cell lines that vary 
with conditions [7]. For examples, the OCT4 biomarker, which was once thought to be an 
excellent marker for discriminating ESCs and SCs, is only transitionally expressed in ESCs 
and is not consistently expressed in different ESCs, especially in old ESCs [7]. Any single 
biomarker that was selected from a very limited number of samples is unlikely to be robust 
enough to  classify  novel  stem cells  when applied alone across various conditions [7].  In  
addition, most of the current biomarkers based on antibodies will  fail  to detect the protein 
signals that are of low abundance, and thus the antibody-based biomarkers naturally exhibit  
low sensitivity. The strategy developed for distinguishing SCs from PCs also may not work for  
discriminating ESCs and iPSCs due to their similarity. 
It  is  challenging  to  discriminate  ESCs  and  iPSCs.  Meta-analyses  of  genome-wide  gene 
expression  data  sets  which  contain  a  large  sample  size  can  circumvent  sample  size 
limitations and generate the unbiased signatures needed to classify ESCs with the aid of 
cluster analysis [8]. A combination of linear models and gene expression profiling was also 
used to classify PCs and SCs [9]. However, the gene signatures cannot be used to distinguish 
iPSCs  and  ESCs  because  the  gene  signatures  are  not  consistently  expressed  across 
different cell lines and conditions [10,11]. The gene expression profiling of iPSCs could be lab-
specific when the batch effect was inappropriately adjusted [10,12]. Furthermore, liner models 
and clustering analysis are associated with a low sensitivity in determining classification, and 
they are also not the optimal mode of data classification with an abnormal distribution [13] and 
with different resources.  Thus, the need for a system that can discriminate all three cell types 
remains.
In  contrast  to  gene expression,  DNA methylation  consistently  varies  between iPSCs and 
ESCs under  various  conditions  [14,15,16].  This  suggests  that  signatures  based  on  DNA 
methylation could be used as biomarkers to discriminate iPSCs and ESCs. In addition, SCs 
express distinct DNA methylation patterns compared to PCs [17]. Thus, DNA methylation-
based biomarkers could provide a promising way to discriminate the three cell lines.   
Applying  mathematical  models  can  quantitatively  and  sensitively  discriminate  biological 
samples [12,18,19]. If systems embedded with mathematical models are trained with large 
sample size, the system can also predict unknown samples. Among mathematical models, 
artificial neural network (NNET) [18] and support vector machines (SVM) [20] are frequently  
employed in biological discriminations [12]. NNET is a form of machine learning and non-
linear statistical data modeling tool which processes data using a connectionism approach 
through an interconnected group of artificial neurons [18]. In most cases, NNET adjusts its 
structure  during  the  learning  phase  according  to  external  or  internal  information  flowing 
through the network [18]. Therefore, NNET is able to cope with noisy and highly dimensional 
datasets, and the network has been utilized in many areas of medicine [18]. Similarly, SVM 
can discriminate complex samples as we previously reported [12].  
In this study, we systematically selected biomarkers by an eigengene score [12], which was 
calculated  from global  methylation  profiling,  and  we  established  a  quantitative  system to 
discriminate iPSCs, ESCs and SCs using mathematical models (i.e. NNET and SVM).
 
Results
DNA methylation profiling of iPSCs, ESCs and SCs 
To investigate the DNA methylation profiling differentially expressed in iPSCs, ESCs and SCs, 
we analyzed genome-wide microarray profiling of these three cell types. In order to avoid cell-
line-specific DNA methylation signatures and to develop a general system to discriminate the 
three cell types, we downloaded and analyzed a large set of data that contains as various 
sources as possible when they are relative to the three cell types (Table S1,  materials and 
methods).  A total of 636 microarrays were used in this study, including 55% SCs, 18% iPSCs, 
and 27% ESCs (Table S1). Various cell sources were included, such as male and female 
iPSCs, fetal  and adult  somatic cells, various tissues, fibroblasts,  iPSC-derived and ESCs-
derived  somatic  cells,  fibroblast-derived  iPSCs,  ESCs-somatic  cell-derived  iPSCs,  and 
epithelial cell-derived iPSCs. 
Unsupervised cluster analysis and correspondence analysis of these samples revealed that 
SCs are clearly separated from PCs, which include iPSCs and ESCs, and that most ESCs 
can  be  separated  from  iPSCs  (Figure  1A).  While  SCs  are  separated  from  PCs  in  first 
correspondence component,  ESCs were somewhat different from iPSCs in respect to the 
correspondence component 2 and component 3 (Figure 1B and 1C). This is consistent with 
the recent finding that iPSCs express distinct methylation profiling compared to ESCs [14] 
and suggests that the DNA methylation could be used as a variable to select biomarkers for 
distinguishing the three cell types. 
DNA methylation biomarker selection
To  improve  the  quantitative  performance  of  our  system,  we  selected  biomarkers  that 
contribute most of variances in this system. This ensures that selected biomarkers capture 
the primary features of data variations.  To circumvent the correlations of gene methylations, 
we employed an eigengene ranking system derived from principal component analysis (PCA) 
as  we  previously  reported  [12]  (materials  and  methods),  instead  of  using  traditional 
approaches that are mostly based on differential analysis. To be conservative and consistent, 
we only used filtered data from one abundant platform (illumina methylation 27K, GPL8490) 
to select biomarkers, and we used other platforms including next-generation sequencing data 
for testing (materials and methods). 
We ranked all  methylation  loci  by  the  eigengene score,  and then selected the  top  ~200 
methylation sites as biomarkers for each group, SCs versus PCs and iPSCs versus ESCs 
(Table 1, Table S2-S3). Interestingly, we found two groups of biomarkers for discriminating 
iPSCs  and  ESCs.  Both  groups  are  important  in  variance  contributions,  and  they  are 
distributed in two separate PCA components. Biologically, one group is located in autosomes 
and another in the x-chromosome (Table S3-S4).   
A quantitative system discriminating iPSCs, ESCs and SCs
To establish a quantitative system for discriminating iPSCs, ESCs and SCs, we employed two 
types of mathematical models, artificial neural network (NNET) and support vector machines 
(SVM). We ran the above models with our data filtered by biomarkers. In both models, we 
measured  the  percentage  of  correction  rate  and  kappa  coefficient,  which  is  a  statistical 
measure of inter-rater agreement for quantitative items. 
To determine the optimal biomarker number for the quantitative system of discriminating SCs 
from PCs, we ran both NNET and SVM by using a series of marker sets, which follow the 
order listed in table 1 and table S2. In each marker set, all samples were randomly sampled 
200 times.  In each run, 70% of random samples worked for training and the rest 30% for  
testing [12] (materials and methods). The accuracy of the 200 runs for each marker set was 
calculated.
With approximately 20 markers, both NNET and SVM discriminated SCs from PCs with an 
average percentage and kappa of 1.0 and 1.0, respectively (Figure 2A). Even with 3 markers 
(cg03273615,  cg18201077,  cg20217872),  both  SVM  and  NNET  could  successfully 
discriminate  these two cell  types  with  similar  accuracy,  with  an  average percentage and 
kappa of approximately 1.0 and 1.0, respectively (Figure 2A). This system became stable, 
even achieved a static state, after approximately 30 markers were applied.  This stable state 
suggests that 30 markers might be good enough for discriminating any types of SCs and PCs. 
Similarly, we also applied the above approach to discriminate ESCs from iPSCs using two 
group  markers,  an  autosomal  group  and  a  x-chromosomal  group  (Table  S3-S4).  The 
autosomal group starts with a 0.75 percentage and 0.4 kappa in both NNET and SVM. A 
stable state is reached with a 0.95 percentage and 0.9 kappa with approximately 100 markers 
(Figure  2B).  With  75  markers,  the  system  reaches  ~90%  accuracy  (Figure  2B).  X-
chromosomal group begins with 0.6 percentage and 0.1 kappa and requires more than 300 
markers to reach 87 percentage and 0.6 kappa value. It seemed that more biomarkers are 
required to reach higher accuracy and to achieve system stability (Figure S1).  Our study 
indicated that the autosomal group performed better than x-chromosomal group and that SVM 
and NNET perform similarly in our biomarker sets. We thereafter used the autosomal group 
as the analysis in this study. This data indicated that discriminating iPSCs and ESCs requires 
at least 100 biomarkers. This also suggested that iPSCs and ESCs samples sources are very 
various, leading to the consequence that more biomarkers (>100) are required to make the 
system robust  and stable.  Together,  our  system,  which  includes math  models  (SVM and 
NNET) and DNA methylation markers, 30 biomarkers and 100 biomarkers respectively for 
distinguishing SCs from PCs and IPSCs from ESCs, can successfully discriminate three cell  
types, SCs, iPSCs, and ESCs.  
The system can be expended for general methylation measurement
Methylation data measured by traditional experiments like bisulfite conversion counting are 
usually presented as discrete percentage. The discrete percentages are highly correlated with 
beta values that come from microarray data as evidenced by a high correlation that exists in  
beta  values  and  percentage  methylation  levels  measured  by  genome-wide  bisulfite 
sequencing of  ESCs [21](Figure 3A).  To  make our  system more applicable  to  biological 
experiments,  we converted the beta value to  a discrete percentage level  as listed in the  
following pairs,  beta value/percentage >0.90/100,  0.9/90, 0.85/80,  0.8/70,  0.75/60, 0.7/40, 
0.6/25, 0.55/20, 0.5/10, 0.4/5, 0.3/2, 0.17/1, and <0.17/0.
Using the conversion data, our system performs similar to the performance with unconverted 
data, and it reaches 100% and 90% accuracy with 30 markers and 100 markers respectively  
for discriminating SCs from PCs and iPSCs from ESCs (Figure 3). The high accuracy with 
converted and unconverted data suggests that our system can be used as a generalized 
application.
Robustness and validation   
To further investigate the robustness of this system, we tested this system using raw data 
without global normalization (materials and methods). This system surprisingly works similarly  
to that with normalized data. With 30 markers and 75 markers respectively for discriminating 
SCs from PCs and ESCs from iPSCs, our system reaches 100% and 90% accuracy (Figure 
4). 
We validated this system using different platforms and resources including data from two new 
platforms,  Illumna  450K  (GPL13534)  (materials  and  methods)  and  next-generation 
sequencing [16] and data generated by another research group looking at aging whose focus 
was unrelated to stem cell research [22]. The performance of our system was tested on each 
platform or resource. In the aging group [22], only SCs are available.  All data was run with at 
least 20 sets of biomarkers; at least 30 to 50 markers were used for discriminating SCs from 
PCs and 170 to 200 markers were used for discriminating ESCs from iPSCs (materials and 
methods).  This  system can  correctly  predict  SCs  from PCs  100% of  the  time  under  all  
conditions, while it discriminates ESCs from iPSCs with ~90% of accuracy (Table 2).  The 
accuracy rates suggest that this system is very robust and predictive.
Cell subtype discrimination
Distinguished DNA methylation patterns have been observed in subtypes of cells, such as the 
subtype of fetal  and adult  somatic cells and the subtype of female and male iPSCs [17].  
Correspondence analysis of  DNA methylation levels of  SCs and iPSCs also showed that 
female iPSCs clearly separate from male iPSCs (Figure 5A) and adult SCs separate from 
fetal  SCs  (Figure  5B).   This  suggested  that  DNA methylation  could  be  used  to  select 
biomarkers for discriminating cell subtypes.  We used the same strategy described above to 
select DNA methylation biomarkers for discriminating two subtypes, iPSCs male and female 
subtypes and SCs fetal and adult subtypes (Table S5-S6). Mathematical models with these 
biomarkers  showed  that  the  accuracy  of  discriminating  female  iPSCs  from  male  iPSCs 
reaches 100% accuracy when using 2 biomarkers (Table S5). When discriminating the adult 
SCs and fetal SCs, 95% accuracy is reached with 80 biomarkers. The high level of accuracy 
indicated that our system could be extended to identify the cell subtypes.    
  
Discussion
For  the  first  time,  this  study  established  a  general  quantitative  system  based  on  DNA-
methylation markers to discriminate three cell types, iPSCs, ESCs, and SCs. Conventional 
methods like the OCT4 based method to distinguish ESCs from SCs have limitations and may 
not be efficient.  Currently, there is no way to discriminate iPSCs from ESCs due to their  
similarity.
SCs are obviously  different  from PCs, which include iPSCs and ESCs. SCs exhibit  DNA 
methylation patterns that can be distinguished from PCs in all  observed conditions so far 
[17,23]. It is therefore reasonable to use DNA methylation as a variable to discriminate SCs 
from PCs although this system does not exist to date. In contrast, iPSCs closely mimic ESCs 
in many aspects such as colony morphology, even gene expressions and microRNA profiling 
[1,2,3,4,5,11,24].  Although previous studies showed that iPSCs generated from single cell  
resources  display  DNA  methylation  variations  compared  with  ESCs  [14,15,23],  these 
variations  could  be  cell-type specific  and condition-dependent  due to  the  limitation  of  its 
sample-size and the pure sample-resources. Here, we collected a large dataset including 
various  cell  line  sources  and  conditions  (Table  S1)  to  determine  if  the  DNA methylation 
pattern varied between iPSCs and ESCs (Figure 1). The DNA methylation pattern revealed 
that iPSCs generally exhibit certain variations compared to ESCs regardless of their originality 
and  conditions.  Therefore,  DNA  methylation  could  be  used  to  select  biomarkers  for 
discriminating iPSCs from ESCs.
Biomarker selections should consider two major aspects, the generalizability of the sample 
and method efficiency.  Condition-specific samples [25] like cell-line specific samples [7] could 
bias biomarker selections. To make our system generalizable, we minimized the cell-line bias 
selection and included various cell line sources (Table S1), such as different cell originality 
and gender. Methods based on differential values are usually employed to select biomarkers;  
however, these methods focus only on the significant differences between variables and fail to 
avoid  variable  correlations  and  redundant  information  from  the  multiple  dimensional 
microarray  data.  Thus,  these conventional  approaches  could  harass biomarker  selections 
[26]. We selected the biomarkers by adopting the unbiased eigengene selection approach as 
we previously reported [12] (materials and methods).  Eigengene-based selection takes care 
of the variable correlations and the redundant information of multiple variables, and it selects  
the independent elements that contribute to most of the variances in the entire dataset. All  
conditions  like  cell  originality  and  other  conditions  have  been  taken  into  account  and 
variations of conditions and cell-originalities have been reflected in the variance contributions. 
Thus, the selected biomarkers should be the most generalizable and the most important ones 
in this system. A quantitative system based on these selected biomarkers should perform 
better than that  one based on biomarkers selected from differential  comparisons. Indeed, 
while  not  reported  here,  we  found  that  a  system  based  on  the  differential  methylation 
performed poorer than our system reported here in term of discriminant accuracy. Therefore, 
the way that we employed here to select biomarkers is efficient and the biomarkers selected 
from general data including various sources should be of general properties.
The  sensitivity  is  of  most  concern  for  biomarker  system  development  [7,25,27]. 
Conventionally,  methods based on PCR or immunochemistry  with  a single biomarker  like 
OCT4 have been frequently used in medical researches for distinguishing ESCs [6,7], but it is 
unlikely for these traditional approaches to provide a sensitive system to discriminate all cell 
types  under  all  conditions  given  the  substantial  heterogeneity  among  the  cell  types  [7]. 
Clustering analysis based on gene expression signatures was proposed to classify ESCs [8];  
however  its  use  is  severely  limited  by  the  natural  low  accuracy  associated  with  cluster 
analysis and the numerous signatures involved in the clustering. Ideally,  a simple system 
should be developed, including a small panel of biomarkers that are easy measured and a 
mathematical  model  that  quantitatively  performs  a  sensitive  judgment.   However,  it  is 
challenging to assemble and validate such a biomarker panel. Here, we employed a machine 
learning system based on NNET and SVM to systematically  and quantitatively validate a 
panel  of  ~200  biomarkers  for  each  group  (Figure  2). NNET  and  SVM,  combined  with 
dimension-reduced approaches like principal component analysis, are advantageous when 
handling non-linear functions for nosey multiple dimension data and have been successfully 
applied in discriminating disease cell lines and molecular complexity [12,18]. NNET and SVM 
with  as  few  as  3  biomarkers  for  determining  SCs  from  PCs  and  with  100  markers  for  
determining iPSCs from ESCs can discriminate the three cell  types with  100% and 95% 
accuracy respectively for two groups (Figure 2). This suggests that our system is the most 
sensitive system to discriminate the three cell types to date.
Robustness  and  prediction  value  are  also  of  concern  in  developing  discriminant  system 
[7,25,27].  Conventional approaches such as PCR, immunostaining and clustering analysis 
are of low robustness and prediction value. We tested our system with raw data without global  
normalization  and  with  discrete  methylation  percentage  data  converted  from  continuous 
variables measured from microarray, and we found that our system 100% and 90% correctly 
discriminates SCs from PCs and iPSCs from ESCs, respectively (Figure 3 and Figure 4). 
When validated by new samples generated from other independent groups and even from 
different  microarray  platform  and  next-generation  high  throughput  sequencing  data,  our 
system continued to correctly predict 100% SCs and 90% of iPSCs from ESCs (Table 2). 
Thus, this system established here is very robust and can be generally applied to discriminate 
the three cells types in medical research.
Furthermore,  Nazor  et  al  recently  revealed  the  distinguished  DNA methylation  patterns 
existing in the subtypes of cells [17], such as the subtype of female against male in iPSCs,  
and the subtype of fetal versus adult in SCs. This suggested that DNA methylation could be 
used  as  a  variable  to  discriminate  the  subtypes  of  cells.  We  extended  our  system  to 
discriminate the subtypes of cells, and our system reached 100% accuracy in discriminating 
female and male iPSCs and 95% accuracy in  classifying adult  and fetal  SCs (Figure 5). 
Concerning the SCs, which contained various tissues with tissue-specific methylation loci, the 
95%  accuracy  with  80  biomarkers,  would  be  very  promising,  and  this  system  could  be 
extended to discriminate other subtypes of cells when more data is available.  
The methylation data for our biomarkers can be measured using traditional methods, and the 
measurement  is  less  expensive  than  microarray  and  antibody-based  immunochemical 
approach. Therefore, this system developed here is a cost effective, accurate and reliable 
discriminant system to distinguish three cell types. This approach lays a fundamental strategy 
to develop other discriminant systems.   
Materials and Methods
DNA methylation data and processing
All  636  methylation  microarray  data  were  downloaded  from  GEO  database 
(www.ncbi.nlm.nih.gov/  geo  /)   (Table S1).  The  methylation  data  was  preprocessed  by 
GenomeStudio  (http://www.illumina.com/gsp/genomestudio_software.ilmn)  and  then  was 
processed using R (http://www.r-project.org/). All methylation values measured by microarray 
were calculated as beta value, ranging from 0 to 1. These values were pre-normalized by  
GenomeStudio using default parameters. Before further analysis, outliers were filtered out in 
basis  of   QC  checking  the  distributions  of  X-chromosome  beta  value  [28]  and   CpG 
methylation [29] and the euclidean distance from samples to group center. After outliers were 
filtered, only 312 out of 399 microarrays generated from the platform GPL8490 (Illumina 27k)  
were available for biomarker selection.  Because the microarray data were not generated at 
the same time, the batch effect needs to be filtered out before combining the microarray 
datasets. An algorithm called ComBat [30], which runs in R environment and uses parametric 
and nonparametric empirical Bayes frameworks to adjust microarray data for batch effects, 
was used to adjust the final methylation values for all datasets.
Biomarker selection
Biomarkers were selected based on an eigengene score, which was defined below as we 
previously reported [12]. 
score = |cor(xi,E)|
|Cor(xi, E)| is the absolute value of Pearson correlation coefficient,  where x i is a vector of 
methylation of ith node, and E eigenvalue derived from principal component analysis.     
Artificial neural networks and support vector machines 
 
Mathematical  models  from  NNET  packages  in  R  were  used  to  perform  artificial  neural 
network (NNET). NNET is machine learning mathematical  model that is designed to emulate 
the architecture of the brain[31]. In NNET, data is processed by neurons that are  organized in 
parallel layers: input, hidden, and output. The neurons of the input layer receive data as a 
methylation value and transmit the input data into the hidden layer neurons that process the 
data using mathematical functions. The processed results are displayed into the output layer 
neurons.  The output neuron with largest value in output layer will be the group that input 
neuron (either iPSCs, ESCs, or SCs) should be.  
We used SVM as we previously  reported [12].  Briefly,  SVM classifies datasets based on 
hyperplanes in which samples can be clustered with the largest separated distances. The R 
package e1071 was used in this study. 
For both NNET and SVM, we randomly sampled 200 times for each biomarker set, from 1 
biomarker to 200 biomarkers, and we used 70% of the samples as a training set and the  
remaining 30% as test data. The accuracy was calculated from the test data set by measuring 
both average percentage correct rate and kappa value. 
Validation and prediction
During validation and prediction, data were normalized from 0 to 1 number in basis of beta 
value  format  from  Illumina  Inc,  without  removing  batch  effect  and  without  further 
normalization. All  27k platform data used for biomarker selections was treated as training 
data, and the samples from 45k platform (GPL13534), the next-generation sequencing [16],  
and the samples from the aging study [22] were used as separate testing sets. The testing 
samples were randomly sampled 200 times, each time using 90% of the samples as input for  
calculating the accuracy. At least 20 biomarker sets were run for each testing set, utilizing 30 
to 50 markers to determine SCs from PCs and 170 to 200 markers to determine ESCs from 
iPSCs. Only markers that overlapped between training and testing data sets were used for 
each run. In the sequencing data, we used the read counts from methylation sites generated  
from sequencing data that was further standardized between 0 and 1. 
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Figure and Table legends 
Figure 1.  Overall methylation profiling of three cell types. A, Clustering analysis revealed 
that SCs were separated from PCs (iPSCs and ESCs). In the PCs subgroup, most ESCs 
were separated from iPSCs. B, Correspondence analysis classified three cell  types, SCs, 
iPSCs, and ESCs. SCs and PCs were separated in first component while most of ESCs and  
iPSCs were separated in second component. C, iPSCs and ESCs were further classified in 
3D space. For visualization purposes, only one subset of data was shown here.
Figure 2. Performance of DNA methylation biomarker system. Accuracy was measured 
as kappa value and accuracy percentage, shown on the Y-axis. The top panel A represents 
SCs discriminating from PCs and the bottom panel B represents ESCs from iPSCs. The X-
axis represents marker number, from 1 marker to 50 markers in SCs versus PCs panel (top), 
and from 1 to 200 markers in ESCs versus iPSCs panel (bottom B). Only data for 50 and 200 
markers for these two groups are shown because the system became a static state after that 
level. 
Figure 3. The discriminating system performs precisely on converted data. A, a high 
correction  relationship  exists  between methylation percentage measured from sequencing 
and the beta value measured from Illumina microarray. B, Our system discriminates the three 
cell types with high accuracy with converted data. For visualization purposes, only percentage 
of NNET was shown here due to its similarity with SVM and the high correlation between 
accuracy percentage and kappa. This practice was also applied to following figures in this  
study.  
Figure 4. Our system works accurately with raw data. Our system reaches the similar 
discriminating power as that with normalized data.
Figure  5.  Cell  subtype  discrimination. A and  B  denote  correspondence  analysis  to  classify 
subtypes of cells. A, the subtype of female and male iPSCs. B, the subtype of fetal and adult  
SCs. C and D show the accuracy of discriminating subtypes of cells. C, the subtype of female 
and male iPSCs. D, the subtype of fetal and adult SCs.  
 
Table 1, Top biomarker list. Left panel, top 10 biomarkers for discriminating SCs from PCs. 
Right panel, top 10 biomarkers for discriminating iPSCs from ESCs. Please see Table S2-S4 
for complete list used in this study. 
Table 2. Prediction profiling of our system.  
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